New treatment may be able to give some cancer patients more time

Four months. It may not seem like a long time to many people, but for those with cancer, it's 120 days they might not have.

A breakthrough treatment for prostate cancer patients is changing that for some. People who've gone through the process have mixed emotions.

Friday night we give you some perspective on provenge.

Ray Schmidlin, Robert Obin, are two men with prostate cancer who know the disease will kill them.

Ray Schmidlin, has prostate cancer, explains his outlook on the cancer outlook, ”It's a matter of when."

They've both been treated with provenge, a therapeutic vaccine using their own blood to slow down the cancer. Certain cells are harvested, altered and infused back into the body to help the immune system attack the cancer. Studies show it can improve a patient's median survival rate by four months, and it reduced patient's risk of death by 22.5 percent. Robert believes it's the reason he's still around.

Robert Obin, has prostate cancer, explains why the new treatment is the reason he is still around, "It's not going to cure me, but that will help me to give me, I don't know, more days?"

Ray says the immunotherapy took a toll on him. The active grandfather tells us he was strapped down for several hours at a time during six weeks of treatment.

Schmidlin explains how stressful the treatment was, "That was pretty stressful. Because you couldn't, you couldn't move."

He's not sure the discomfort and confinement was worth it.

Schmidlin explains he doesn’t know if the treatment is worth it, "If I'm going to live 60 months, I don't want to spend the money and the time to live 64 months."

Jorge A. Garcia, MD, Director Advanced Prostate Cancer Program Cleveland Clinic, explains how people need to talk about the new treatment, "I think it's a controversial topic."

Ray's physician, Doctor Jorge Garcia of the Cleveland Clinic says there are misconceptions about provenge.

Doctor Garcia, MD, describes why some people do not like the treatment, "The patient automatically believes if I get the treatment, I'm going to live four months more, and that's inaccurate."

Garcia says some live longer but some don't make it to four months. It's not for all prostate cancer patients. It's designed for those who show few or no symptoms, but have a form of the disease that has spread and is resistant to hormonal therapy. Garcia says it doesn't lower PSA levels, shrink tumors, or reduce symptoms like bone pain.

Doctor Garcia, MD, explains that it could help, "But yet, you're likely to live longer."

While the doctor believes provenge is a breakthrough, he says its important patients like Ray and Robert know it may or may not be the right option for them.

Provenge costs $93,000. It's now covered by Medicare, but the time it takes for the treatment seems to be driving some doctors and patients away.

Dr. Rafat Ansari is using the therapy on some of his patients, locally, and to see a story I did with him in September you can click on the bottom of this story.

Recent reports show zytiga, a newly approved pill for advanced prostate cancer, that's also been shown to prolong life by four months in clinical trials, is gaining in popularity.

It costs $5,000 a month, and usually takes eight months to complete the drug cycle.

For more information on the patients getting the treatment locally visit: http://www.wndu.com/mmm/headlines/A_new_treatment_for_advanced_prostate_cancer_will_save_lives_129352668.html

MEDICAL BREAKTHROUGHS
RESEARCH SUMMARY

TOPIC: BREAKING DOWN A BREAKTHROUGH: PROS & CONS FOR PRS
REPORT: MB #3398

PROSTATE CANCER: Aside from non-melanoma skin cancer, prostate cancer is the most common cancer among men in the United States. There were 240,000 estimated new cases and deaths from prostate cancer just in 2011. (Source: CDC)

PROVENGE: Provenge is a cell therapy that aims to train the immune system to attack tumor cells. It's made using cells from a patient's own immune system, so it cannot be warehoused like many other drugs. The process of making Provenge involves the exposure of a patient's immune cells to a protein that functions as a prostate cancer-associated antigen. An antigen is a substance that causes the body to react with an immune response. This process activates the patient's immune cells against prostate cancer to help the immune system better fight the disease. The most common side effects reported with PROVENGE are chills, fatigue, fever, back pain, nausea, joint ache, and headache. These are not all the possible side effects of Provenge treatment. (Source: Dendreon.com, Provenge.com)

THE DRUG DEBATE: A new survey of cancer doctors is found the miracle drug has some cons as well. The percentage of patients who are deemed eligible for Provenge seems to be going down, declining from 37% to 24%. Of the 67% of total responders who did not have access to Provenge at the time of the survey, just 50% indicate they will prescribe Provenge once it becomes available. (Source: Forbes.com)

A NEW MIRACLE? A new study published in the New England Journal of Medicine shows, the newly approved prostate cancer pill Zytiga may extend life by up to four months in men with spreading cancer who have already been treated with chemotherapy. It inhibits a protein that helps form male hormones. Men who took the new pill also saw greater responses in levels of prostate-specific antigen (PSA) than men who received placebo. This survival edge was considered so significant that men who received the placebo were permitted to switch to the new drug before the study was completed.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
WNDU - Channel 16 54516 State Road 933 South Bend, IN 46637 Front Desk: 574-284-3000 Newsroom: 574-284-3016 Email: newscenter16@wndu.com
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 137299753 - wndu.com/a?a=137299753